By SPC New Staff
Secukinumab (Cosentyx, Novartis) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate to severe hidradenitis suppurativa (HS) with a favorable safety profile, according to data presented at the 2022 European Academy of Dermatology and Venereology (EADV) Congress (abstract LB-3549).
The trials assessed two secukinumab dose regimens across 16-week (vs. placebo) and 52-week treatment periods. Results showed a significantly higher proportion